Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Sep;13(9):820-6.
doi: 10.1093/ntr/ntr078. Epub 2011 Apr 18.

A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States

Jon O Ebbert  1 , Ivana T Croghan, Herbert H Severson, Darrell R Schroeder, J Taylor Hays
Affiliations
Clinical Trial

A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States

Jon O Ebbert et al. Nicotine Tob Res. 2011 Sep.

Abstract

Introduction: Long-term smokeless tobacco (ST) use is known to increase the risk for oropharyngeal cancer, heart attack, and stroke. Varenicline has recently been demonstrated to increase ST abstinence rates among Swedish snus users. We have conducted a pilot study to obtain preliminary evidence of efficacy of varenicline for the treatment of ST users in Midwestern United States.

Methods: We conducted a randomized, placebo-controlled Phase II clinical trial to evaluate the potential efficacy of 12 weeks of varenicline for the treatment of ST users with an a priori decision rule that a 1-tailed p < .20 for the comparison of the primary endpoint was evidence to conclude that future studies were warranted. Subjects were followed for 6 months after randomization.

Results: We randomized 76 subjects (38 varenicline and 38 placebo). Subjects were similar at baseline with a mean age of 41 years, and all were male. The biochemically confirmed point prevalence tobacco abstinence rates at end of treatment were 55.3% for varenicline and 42.1% for placebo (p = .126) and 47.4% and 31.6% (p = .080), respectively, at 6 months. Point prevalence ST abstinence rates at end of treatment for varenicline were 57.9% and 42.1% for placebo (p = .084) and 57.9% and 31.6% (p = .011), respectively, at 6 months. Varenicline was associated with significantly less craving compared with placebo. Varenicline was well tolerated with nausea and sleep disturbance being the most common side effects.

Conclusions: Varenicline decreases craving and may be effective for increasing tobacco abstinence rates among ST users. Larger trials may be warranted to confirm these results.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Craving on the Minnesota Nicotine Withdrawal Scale modified for smokeless tobacco users
See this image and copyright information in PMC

References

    1. Arnau RC, Meagher MW, Norris MP, Bramson R. Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients. Health Psychology. 2001;20:112–119. doi:10.1037/0278-6133.20.2.112. - PubMed
    1. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
    1. Benowitz NL, Ahijevych K, Hall S, Hansson A, Henningfield J, Hurt RD, et al. Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research. 2002;4:149–159. doi:10.1080/14622200210123581. - PubMed
    1. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncology. 2008;9:667–675. doi:10.1016/S1470-2045(08)70173-6. - PubMed
    1. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addictive Behaviors. 2007;32:912–923. doi:10.1016/j.addbeh.2006.06.028. - PubMed

Publication types